Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $56.33.

Several analysts have recently commented on AGIO shares. Scotiabank raised their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th.

Agios Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ:AGIO opened at $38.97 on Wednesday. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The company has a 50-day moving average price of $50.02 and a 200 day moving average price of $46.76. The company has a market cap of $2.22 billion, a P/E ratio of 3.43 and a beta of 0.80.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AGIO. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares during the period. CWM LLC lifted its stake in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.